Antimicrobial Therapy for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria.
10.3904/kjm.2018.93.5.439
- Author:
Yu Mi WI
1
;
Cheol In KANG
Author Information
1. Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea. collacin@hotmail.com
- Publication Type:Review
- Keywords:
Gram-negative bacteria;
Carbapenem;
Drug resistance;
Treatment outcome
- MeSH:
Acinetobacter baumannii;
Aminoglycosides;
Anti-Bacterial Agents;
Colistin;
Drug Resistance;
Fosfomycin;
Gram-Negative Bacteria*;
Humans;
Klebsiella pneumoniae;
Korea;
Pseudomonas aeruginosa;
Treatment Outcome
- From:Korean Journal of Medicine
2018;93(5):439-446
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Carbapenem-resistance emerging in Gram-negative pathogens, such as Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, has become a major human health problem globally. The therapeutic options available for carbapenem-resistant pathogens are very limited. Antibiotics such as colistin, tigecycline, fosfomycin, and aminoglycosides are often the only ones that can be used to treat carbapenem-resistant pathogens. Carbapenem may still be an option in certain circumstances. The administration of combination therapy for carbapenem-resistant pathogens is controversial. This review presents the current knowledge of available antimicrobial therapeutic options for infections due to carbapenem-resistant pathogens in Korea.
